Efficacy and Safety of Latanoprost/Timolol Fixed-Dose Combination in Glaucoma Treatment: A 20-Year Review - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Latanoprost/Timolol Fixed-Dose Combination in Glaucoma Treatment: A 20-Year Review

  • By

  • Jose Martinez-de-la-Casa

  • Pedro Corsino

  • Andrzej Grzybowski

  • Andrew Tatham

  • Shivani Ohri Vignesh

  • Tarek Hassan

  • January 8, 2026

Share

  • 1

    Glaucoma affects approximately 76 million people globally, with projections of 95.4 million by 2030 and 112 million by 2040.

  • 2

    Latanoprost, a first-line therapy, effectively reduces intraocular pressure (IOP) by 25%-35% with once-daily dosing.

  • 3

    Fixed-dose combinations like latanoprost/timolol simplify treatment regimens, potentially improving patient adherence and quality of life.

  • 4

    Studies show high patient satisfaction with latanoprost/timolol fixed combination, with 92% satisfaction reported after switching from other therapies.

  • 5

    Patient-reported outcome measures (PROMs) are essential for evaluating the impact of glaucoma treatments on adherence and quality of life.

Original Source(s)

Efficacy and Safety of Latanoprost/Timolol Fixed-Dose Combination in Glaucoma Treatment: A 20-Year Review

  • by Jose Martinez-de-la-Casa, Pedro Corsino, Andrzej Grzybowski, Andrew Tatham, Shivani Ohri Vignesh, Tarek Hassan

  • January 8, 2026

Related Content

Effect of low-cost direct ophthalmoscopy training on glaucoma disc assessment by allied ophthalmic personnel students: a controlled pre-post study

Trends and Regional Differences in the Prescription of Prostaglandin Analogs for Glaucoma in England from 2019 to 2024

Evaluation of Serum Levels of Iron, Zinc, and Magnesium in Patients with Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Case-Control Analysis